Research Topics
Species | J Bolanos-MeadeSummaryAffiliation: Johns Hopkins University Country: USA Publications
| Collaborators
|
Detail Information
Publications
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamideLeo Luznik
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
Biol Blood Marrow Transplant 14:641-50. 2008..02). Nonmyeloablative HLA-haploidentical BMT with posttransplantation Cy is associated with acceptable rates of fatal graft failure and severe aGVHD or cGVHD...
Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302Javier Bolaños-Meade
Hematologic Malignancies, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
Biol Blood Marrow Transplant 19:481-5. 2013..We found no significant differences in lymphocyte total or subpopulation counts among the 4 treatment arms, and no notable influence on outcomes...- HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell diseaseJavier Bolaños-Meade
Hematologic Malignancies and Bone Marrow Transplantation Program, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and Johns Hopkins University School of Medicine, Baltimore, MD 21231 1000, USA
Blood 120:4285-91. 2012..Graft failure, 43% in haploidentical pairs, remains a major obstacle but may be acceptable in a fraction of patients if the majority can be cured without serious toxicities... - 5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantationJavier Bolaños-Meade
George W Santos Bone Marrow Transplant Service, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
Biol Blood Marrow Transplant 17:754-8. 2011..5 days (127-1411). These results further suggest that 5-azacytidine is an active agent after failing an allogeneic bone marrow transplant, and prospective studies are warranted... - Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimenJ Bolanos-Meade
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
Bone Marrow Transplant 43:477-80. 2009..The combination of fludarabine and alemtuzumab is an effective and well-tolerated salvage conditioning regimen for patients who experience graft failure after blood or marrow transplants... - Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphomaJavier Bolaños-Meade
George W Santos Bone Marrow Transplant Service, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
Biol Blood Marrow Transplant 13:1185-91. 2007..The administration of oral cyclosporine followed by interleukin-2 and gamma-interferon is generally not well tolerated, and does not appear to be an effective method to induce autologous GVHD in patients receiving autologous PBSC grafts... 
Update on the management of acute graft-versus-host diseaseJavier Bolaños-Meade
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
Curr Opin Oncol 18:120-5. 2006..Recent advances in its prevention and therapy are giving new hope to patients with this disease. This review covers the major advances in prophylaxis and therapy for this problem...- Lymphocytic pneumonitis as the manifestation of acute graft-versus-host disease of the lungJavier Bolaños-Meade
Blood and Marrow Transplant Program, University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, USA
Am J Hematol 79:132-5. 2005..Its diagnosis requires work-up to rule out an infectious etiology and a biopsy to confirm histology... - Autologous stem cell transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin's lymphomaA P Rapoport
University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
Bone Marrow Transplant 34:883-90. 2004..5 years, EFS=87%). There were no treatment-related deaths during or after the CC phase. Post-transplant CC is feasible and well tolerated. The impact of this approach on EFS should be evaluated in a larger, randomized study... - Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphomaA B Fassas
Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA
Br J Haematol 112:237-41. 2001.... - Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseasesR A Brodsky
Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, MD 21205 2196, USA
Bone Marrow Transplant 42:523-7. 2008..Nonmyeloablative, HLA-haploidentical BMT with post-transplant CY is a promising approach for patients with life-threatening nonmalignant hematologic disease who lack an HLA-matched sibling donor... - Tamoxifen-based treatment induces clinically meaningful responses in multiple myeloma patients with relapsing disease after autotransplantationA B Fassas
Department of Internal Medicine, Greenebaum Cancer Center, University of Maryland, Baltimore, USA
Leuk Lymphoma 42:1323-8. 2001..The regimen was very well tolerated. Speculations about a possible mechanism of action of tamoxifen in multiple myeloma are discussed... - Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanningYvette L Kasamon
Johns Hopkins University, Baltimore, Maryland, USA
Biol Blood Marrow Transplant 15:242-8. 2009..The favorable outcome achieved here in historically poor-risk patients warrants further, more definitive investigation of treatment modification based on early PET scanning... - Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcomeYvette L Kasamon
Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231, USA
Biol Blood Marrow Transplant 16:482-9. 2010..55, P = .03 for 3-4 vs fewer allele mismatches). Thus, greater HLA disparity does not appear to worsen overall outcome after NMA haploidentical BMT with high-dose posttransplantation cyclophosphamide... - Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemiaJudith E Karp
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
Leuk Res 34:877-82. 2010..Short OS and DFS correlated with adverse cytogenetics, regardless of age or treatment in CR. The addition of allogeneic BMT in CR translates into long OS and DFS in the majority of eligible patients... - High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host diseaseLeo Luznik
Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
Blood 115:3224-30. 2010..These results suggest that high-dose posttransplantation cyclophosphamide is an effective single-agent prophylaxis of acute and chronic GVHD after BuCy conditioning and HLA-matched BMT (clinicaltrials.gov no. NCT00134017)... - Chronic graft-versus-host diseaseJavier Bolaños-Meade
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
Curr Pharm Des 14:1974-86. 2008..Novel agents such as pentostatin, mycophenolate mofetil, rituximab, extracorporeal photochemotherapy, etc. are improving the outcome of steroid refractory chronic graft-versus-host disease... - Blood and marrow transplantation for sickle cell disease: overcoming barriers to successJavier Bolaños-Meade
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
Curr Opin Oncol 21:158-61. 2009..The objective of this report is to review the most recent clinical trials involving blood and BMT for SCD and to discuss novel approaches to overcome the many barriers to successful use of BMT for SCD...